Biotech Argenx's autoimmune phase 3 hits goals, teeing up FDA filing

A phase 3 trial of Argenx’s efgartigimod in generalized myasthenia gravis (gMG) patients has hit its primary endpoint, setting the European biotech up to file for FDA approval by the end of the year.